A hidden Markov model-based algorithm for identifying tumour subtype using array CGH data by Zhang, Ke et al.
RESEARCH Open Access
A hidden Markov model-based algorithm for








From BIOCOMP 2010. The 2010 International Conference on Bioinformatics and Computational Biology
Las Vegas, NV, USA. 12-15 July 2010
Abstract
Background: The recent advancement in array CGH (aCGH) research has significantly improved tumor
identification using DNA copy number data. A number of unsupervised learning methods have been proposed for
clustering aCGH samples. Two of the major challenges for developing aCGH sample clustering are the high spatial
correlation between aCGH markers and the low computing efficiency. A mixture hidden Markov model based
algorithm was developed to address these two challenges.
Results: The hidden Markov model (HMM) was used to model the spatial correlation between aCGH markers. A
fast clustering algorithm was implemented and real data analysis on glioma aCGH data has shown that it
converges to the optimal cluster rapidly and the computation time is proportional to the sample size. Simulation
results showed that this HMM based clustering (HMMC) method has a substantially lower error rate than NMF
clustering. The HMMC results for glioma data were significantly associated with clinical outcomes.
Conclusions: We have developed a fast clustering algorithm to identify tumor subtypes based on DNA copy
number aberrations. The performance of the proposed HMMC method has been evaluated using both simulated
and real aCGH data. The software for HMMC in both R and C++ is available in ND INBRE website http://ndinbre.
org/programs/bioinformatics.php.
Background
Tumor progression is a complicated biological process
that comes with enormous genetic and molecular
changes, such as chromosome aberration, gene muta-
tions, and activation or inhibition of transcriptional
pathways. The abnormal genetic changes often show
high variability even among tumors within the same his-
topathological subtype and anatomical origin, which
may lead to variation in clinical outcomes. For example,
a subtype of colorectal cancer, hereditary nonpolyposis
(HNPCC), is characterized by dominant genetic defects
in DNA mismatch repair pathway and HNPCC patients
have higher 5-year survival than other subtypes of color-
ectal cancer patients[1]. When genetic aberration is spe-
cific to a subset of tumors, it provides potent targets for
chemotherapy. Examples include trastuzumab and lapa-
tinib for treating HER2-positive breast cancers [2],
tamoxifen for treating ER-positive breast cancers[3,4],
and gefitinib and erlotinib for non-small cell lung cancer
with EGFR mutations [5-9].
DNA copy number aberration is a striking feature of
tumor cell. During tumor progression, chromosome is
subjected to dramatic change in that DNA segments are
amplified, deleted, or translocated. Comparative genomic
hybridization (CGH) technology has been a widely used
tool for detecting changes in chromosome fragments.
The advancement of array technology has enabled
researchers to conduct array CGH (aCGH) study for
profiling genome-wide chromosome variations using
high density array, such as single nucleotide polymorph-
ism (SNP) array that contains from 100K to 3M SNP
markers [10]. Such high dimensional DNA copy number
data reveals genomic heterogeneity in many cancer
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subtype at SNP copy number level [11].
Multiple clustering methods, including hierarchical
clustering (HC), Naive Bayes, K-nearest neighbours, sup-
port vector machine, probability model-based clustering,
and nonnegative matrix factorization (NMF), have been
developed and applied for aCGH data to identify tumor
subtypes based on the DNA copy number aberrations
[12-15]. We have previously developed a revised version
of NMF that showed improved performance for aCGH
clustering when testing on three tumor types, non-small
cell lung carcinoma, colorectal cancer and malignant
melanoma [16]. However, all these aforementioned meth-
ods fail to account for the spatial correlation between
SNPs, and the correlation between adjunct SNPs could
be as high as 0.99 for high density SNP array such as
Affymetrix 500K. We therefore developed a mixture
model based clustering method for tumor subtype classi-
fication that uses hidden Markov model (HMM) to
account for the spatial correlation in aCGH data.
Shah et al. [17] have proposed a similar HMM based
clustering method to account for spatial correlation, but is
fundamentally different from our clustering method in a
number of ways First, the models are different. They pro-
posed a Bayesian hierarchical model, nonetheless we fit a
hidden Markov model to the data directly, therefore it has
less unknown variables and decreases the risk of model
overfitting. Secondly, they use expectation maximization
(EM) like algorithm to estimate variables, and we use max-
imum likelihood based method that is computationally
more efficient. Thirdly, our algorithm automatically finds
the optimal number of groups and converges to the opti-
mal grouping. Fourthly, we developed a machine learning
clustering algorithm and have implemented it using C++
parallel programming for fast computation. Finally, we
pre-process the raw aCGH data by segmenting the chro-
mosome prior to clustering. The segmentation step nor-
malizes aCGH data that usually contains high frequency of
intensity noise. We show the performance of the proposed
HMM-based clustering (HMMC) method by applying it
to simulated data and aCGH glioma data.
Methods
We first describe the data pre-processing procedure, our
HMM model and the model fitting for a cluster of
aCGH samples. Then we describe the machine learning
algorithm that uses HMM models to cluster tumors.
Finally, we introduce our fast implementation for the
clustering algorithm and the approach to find the opti-
mal number of groups.
aCGH data segmentation
Raw data from Affymetrix SNP array was preprocessed
using the open source R package aroma.affymetrix with
the default parameters [18]. The resulting SNP-level
copy numbers were segmented using circular binary seg-
mentation (CBS) method within aroma.affymetrix [19].
The break points predicted by CBS at each sample were
then summarized across all samples and the segments
between pairs of adjunct break points were identified
and the mean copy number of each segment was calcu-
lated for clustering analysis. Because tumor specimen is
often contaminated with normal tissues that are adja-
cent to them, which would complicate the analysis and
introduce false negatives, it is necessary to conduct
quality control to remove the normal contamination
first. We developed a machine learning algorithm to
identify and filter out contaminated samples based on
segmented copy number data. To conduct the quality
control, we first chose two groups of samples; one with
the highest number of copy number alteration regions
and the other being normal samples. These two groups
of samples served as a training dataset for a Random
Forest classifier [20] that was used to distinguish tumors
and normal samples and identify signatures for tumor
samples. The out of bag error rate of this classifier is
usually very low (<5%). The trained classifier was then
applied to all aCGH samples and a score of probability
to be contaminated was calculated for each sample.
Samples with a probability of more than 50% of contam-
ination were excluded from further clustering analysis.
HMM model fitting
We use a mixture HMM model to represent the clusters
of tumor samples in that each cluster or subtype of
tumors is modelled by a single HMM. Let t = 1,.., T,
denote the DNA segments of aCGH data. Suppose there
are G clusters in total and there are ng samples in clus-
ter g, where g = 1,..., G. The HMM model for cluster g
is demonstrated in Figure 1. The hidden state at seg-
ment t is denoted as xg(t), which is the true copy num-
ber of segment t and is unknown. The observed mean
copy number for segment t and sample j is denoted as
ygj(t) where j = 1, ..., ng. The transitional probability
from state t-1 to t is denoted as Pg(t) and the emission
probability from state t to observation ygj(t) is denoted
as Pgj(t).
Based on the distribution of segmentation copy num-
ber data, we choose 6 states, xX{0.1, 1.5, 2, 3, 4, 5}. The
transitional probabilities between states are given in a
multinomial distribution that was empirically estimated
from the raw data. For example, for the 79 glioma sam-
ples we discuss in the results section, the transitional
probability between the same states is 0.56, and is 0.088
otherwise. Lognormal distribution is widely used to
model DNA copy number [21]. We let the emission
probability follow a log-normal distribution with the
hidden state value being the mean of the normal
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tribution was empirically estimated from raw data using
the mean standard deviation of segment copy number
across all samples. Viterbi algorithm is used to fit this
HMM model to a cluster of tumor samples. Viterbi
algorithm is an efficient algorithm that uses a dynamic
programming approach to estimate the hidden states
from segment 1 to T and to calculate delta value, Δg,
which is the log-likelihood for the model fitting of clus-
ter g. We have implemented Viterbi algorithm in both R
and C++ programming environment.
Sample clustering
The optimal clustering is determined by the maximum
sum of delta values from all groups. It is computation-
ally infeasible to perform HMM fitting and calculate
delta sum values for every possible clustering because
the number of clustering for n samples G groups is G
n.
We have developed a computationally efficient algo-
rithm for finding the clustering optima.
The algorithm searches the optimal clustering as fol-
lows. First, for a given number of groups G, we run a
NMF algorithm that was developed earlier to prelimina-
rily cluster the samples. The NMF algorithm has been
described previously [16]. Though NMF classifies aCGH
data without considering the correlation between mar-
kers, it has been shown to discover genomic signatures
in various types of tumors [11,16]. Thus, the clustering
result of NMF serves as a starting point for HMM clus-
tering. Secondly, we fit a HMM for each cluster from
the previous step and calculate the sum of delta values,
Δ1, ..., ΔG. This is the log-likelihood for the current opti-
mal clustering. Thirdly, based on the current optimal
clustering, we randomly select 2 samples, and re-assign
the group labels to them. We then perform HMM
model fitting and calculate the log-likelihood for the
new clustering. If the new log-likelihood is greater than
the optimal log-likelihood, we update the optimal clus-
tering with this new clustering. Fourthly and finally, we
repeat the last step a number of times, and stop until
the optimal log-likelihood remains unchanged for m
times of consecutive random clustering. We find that m
=n
2 is sufficient for HMMC to converge to the optimal
clustering. This workflow of clustering procedure is illu-
strated in Figure 2.
We have use both R and C++ to implement this clus-
tering algorithm. As step 3 can be performed simulta-
neously for multiple random clustering, we
implemented a parallel computing version of HMMC to
decrease the computation time. This was accomplished
using the OpenMP package [22] within C++ to allow
the random clustering and HMM fitting to be carried
out across multiple threads in a multi-core machine.
Each thread can update the optimal clustering and all
threads share the same optima. We have tested this pro-
gram in Dell PowerEdge R910 workstation that has 32-
cores and the parallel computing increased efficiency by
an order of magnitude.
Model selection
One of the most difficult questions about clustering pro-
blem is to determine the number of groups, G. Our
HMMC algorithm relies on a given G to find the opti-
mal clustering. Thus model selection is needed to deter-
mine the best number of groups.
We use the Bayesian Information Criterion (BIC), a
widespread statistical tool to conduct model selection.
BIC is defined as follows:
BIC = −2lnL + k × ln(n),
where L is the likelihood which measures how good
the HMM model approximate the data, k is the number
of parameters used in the model, and n is the number
of samples. The second term, kln(n), serves as a penalty
on the number of parameters used in the model to
avoid overfitting. Thus, the magnitude of penalty
increases as the number G increases. A preferred model
is selected upon a lower BIC value that indicates rela-
tively higher likelihood as well as relatively lower risk of
overfitting.
Figure 1 A hidden Markov model for a cluster of tumor aCGH samples. There are n_g samples in cluster g, and the graph shows three
DNA segment, t-1, t, and t+1. X is the unobserved copy number for each segment and y is the observed mean intensity value for each sample.
Pg is transitional probability and Pgj is emission probability.
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where Δg is the delta value of the gth group. Because
the parameters for transitional and emission probability
are empirically estimated, the number of unknown para-
meters k in BIC is equal to the number of hidden states.
For an aCGH dataset with G groups and T segments,
the number of parameters is equal to T × G. Thus, the




g + T × G × ln(n).
We run HMMC for a range of values of G, and select
the optimal G with the smallest BIC.
Cross-validation for testing stability of HMMC
To assess the stability of HMMC results, we conduct a
cross-validation as described earlier [16]. After complet-
ing HMMC for the entire dataset, we perform cross-vali-
dation as follows. We randomly leave 10% of samples out
and apply HMMC to the remaining 90% of samples and
compare the clustering results with the original one. The
number of samples that are assigned to a different sub-
group other than the original result is counted as errors.
We repeat this procedure 100 times and calculate the
error rate, which represents the stability of the clustering
algorithm with respect to the permutation of samples.
Results
Simulation study
In order to test the performance of HMMC, we con-
ducted simulation study to compare HMMC with NMF
clustering. We created two groups of aCGH data with
10 samples per group and 100 segments per each sam-
ple. For the first group, all data were generated from a
normal distribution with mean equal to 2 and standard
deviation equal to s, which was variable between differ-
ent experiments. For the second group, the copy num-
ber of all segments followed a normal distribution as
well. This normal distribution was the same as the first
group, except that 3 segments in the middle of genome
had a mean equal to 4 such that these 3 segments were
amplified. In order to introduce random noise, we ran-
domly drew 40 segments in all samples and increased
their copy number values by 2 (their mean was equal to
4). Thus these 40 segments were randomly amplified
segments. Furthermore, AR(1) correlation was intro-
duced into the data. Considering the high correlation
between SNPs in the high density SNP array, we set the
pho value of AR(1) to be 0.9.
We used HMMC and NMF to cluster the two groups
with s value varying from 0.5 to 2. For each s, 200
aCGH datasets were generated and the number of sam-
ples misplaced for either method was counted. The
error rate curves are shown in Figure 3.
The error rates of both HMMC and NMF increase
as the standard deviation s increases. The error rates
o fH M M Ca r ei nt h er a n g eo f3 %t o8 . 5 % ,w h e r e a s
those for NMF are between 7.9% and 17.6%. There-
fore, the chance for HMMC to incorrectly classifying
Figure 2 Workflow of HMMC clustering procedure. The procedure stops when the optimal clustering is not updated for m = n
2 comparisons
where n is the number of samples.
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lation study.
Glioma data
Glioma tissue aCGH data were acquired from Reposi-
tory for Molecular BRAin Neoplasma DaTa
(REMBRANDT) [23]. We obtained Affymetrix 500K
SNP array data and the corresponding clinical informa-
tion for 79 glioma patients. The aCGH data was first
processed using aroma.affymetrix software and was then
segmented using circular binary segmentation method.
This preprocessing step reduced the number of markers
from 500K to 5321 segments. The segmented data was
used for further analysis.
The first question to be addressed is the computa-
tional performance of HMMC when it is applied to
high-dimensional data. We first test the convergence
r a t eo fH M M Cf o rg l i o m aa C G Hd a t aa s s u m i n g2
groups. As shown in Figure 4A, the log-likelihood of
HMMC increases rapidly in the first 4,000 cycles of
clustering, and it remains stable after 5,000 cycles. The
log-likelihood reaches its maximum at approximately
15,000 cycles, and the computation stops after an addi-
tional 79
2 = 6241 cycles.
Secondly, we tested the computation time for different
number of samples. Random samples were drawn from
the 79 glioma data. The numbers of random samples
was from 10 to 95 and the number of groups was
a s s u m e dt ob e2 .W eu s e daD e l lP o w e r E d g eR 9 1 0t o
run 20 threads simultaneously for this test. Figure 4B
shows the curve of computation time. For 10 samples, it
took less than 20 minutes. For 95 samples, it took about
2 hours to find the optimal clustering. The computation
time is approximately linear to the number of samples
(O(n)). Therefore, our clustering algorithm is computa-
tionally efficient and it achieves O(n) for the computa-
tional complexity.
To find the optimal number of groups, we conducted
model selection using BIC. We ran HMMC for the
number of groups G from 2 to 6, and calculated the
corresponding maximum log-likelihood and BIC. The
results are shown in table 1. The maximum log-likeli-
hood increases as the number of groups increases
because the model has a better fit for the data as the
number of parameters increases. The BIC value was
-304,617 for 2 groups, then it decreased to -305,030 for
3 groups, and then increased as the number of groups
increased. Thus, the optimal number of groups is 3
because it gave the minimum value of BIC.
Figure 5 shows the heatmap of clustering the glioma
samples into 3 groups. Each row of the heatmap is a glioma
sample, and each column is a DNA segment. There are 79
rows and 5,321 columns totally. The segments are sorted
in the order of genomic positions from chromosome 1 to
22. Sex chromosome was not included to avoid bias on
gender. Yellow indicates amplification and blue indicates
deletion. The three groups are shown with the black hori-
zontal lines in the heatmap. Group 1 is characterized by
large area of deletion in chromosome 8. Group 2 has
amplification in various regions of chromosome 2 to 6 and
deletion in chromosome 17 and 18. Group 3 appears to
have sparse aberrations in random regions.
To verify the clustering results, we performed survival
analysis to the 3 groups. The Kaplan-Meier curves are
shown in Figure 6. The blue line is group 1, the green is
g r o u p2a n dt h er e di sg r o u p3 .T h em e d i a ns u r v i v a l
Figure 3 The error rates for simulated data. HMMC and NMF were tested on the same simulated data. The x axis s is the standard deviation
that was used to generate the data. The blue curve is the error rates of HMMC, and the red curve is for NMF.
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and 3 are 1,698 and 1,337 days, respectively. Group 1
has a significant lower overall survival than group 2 and
3. The overall P value by log-rank test is less than
0.0001. Therefore, HMMC successfully clustered glioma
samples based on aCGH data and the resulting tumor
subtypes were associated with clinical outcomes. As dis-
cussed previously, group 2 manifests with large seg-
ments of deletion in chromosome 8. Thus genomic
signature is identified for poor clinical outcome and
they can serve as prognostic biomarkers. Upon identifi-
cation of genes located in these abnormal genomics
regions, we can discover the potential target for cancer
therapy.
Discussion
Genomic information has been increasingly used for
molecular classifications of tumors because it provides a
more objective view than histopathological approach
a n di ts h e d sl i g h to nt h em o l e c u l a rm e c h a n i s m so f
tumor heterogeneity. The global gene expression of
major tumor types has been extensively studied for sub-
type identification [24-27]. The fast development of SNP
a r r a yh a sm a d ei tp o s s i b l et oc h a r a c t e r i z et u m o rs u b -
types based on the genomic DNA copy number, none-
theless, the computational and statistical methods in
this area is still under-developed. In many aspects, DNA
copy number is better than RNA expression data in
terms of genomic signature and diagnostic or prognostic
biomarkers. DNA is much easier to store than RNA
because DNA is a stable molecule whereas RNA is tran-
sient and easy to degrade. In addition, RNA has to be
collected from fresh tissues whereas DNA can be iso-
lated from frozen or paraform tissues even after years of
storage. Furthermore, DNA aberration is preserved in
the cell and can be passed to daughter cells via mitosis,
whereas RNA expression is unstable and RNA levels are
affected by many factors such as cell cycle, environmen-
tal and physiological factors. Therefore, tumor classifica-
tion and genomic signature identification based on
DNA copy number have extensive applications and
improvements in the computational and statistical
Figure 4 Computational performance for glioma data. A. The log-likelihood of HMMC converges rapidly to its maximum. B. The
computational time of HMMC is linear to the sample size.
Table 1 Model selection for glioma data
#Group 2 3 4 5 6
Maximum log-likelihood 162406 167661 169978 172476 175554
BIC -304617 -305030 -299567 -294466 -290524
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Page 6 of 9Figure 5 Heatmap of glioma clustering. 79 glioma samples with 5,321 segments were clustered into 3 groups using HMMC. Sample names
are labelled on the right side, and chromosome number is marked at the bottom. Yellow denotes amplification and blue denotes deletion. The
three groups are labelled with number 1 to 3 on the left side of the graph.
Figure 6 Kaplan-Meier curves of glioma clusters. The 79 glioma patients were clustered into 3 groups using HMMC. The Kaplan-Meier curves
for overall survival time in days were shown. The blue line is group 1, green is group 2, and red is group 3. The P value by log-rank test is less
than 0.0001.
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analysis.
Most current statistical and data mining methods for
aCGH data were developed from expression microarray
analysis. An important difference between aCGH data
and mRNA expression data is the high spatial correla-
tion between neighboring SNPs in the aCGH data. The
correlation between genes in expression microarray is
relatively less and ignored by most methods that have
been developed for such data. Thus most methods
developed for expression microarray may yield signifi-
cant false positives and false negatives when applied to
the aCGH data. Here we proposed a clustering algo-
rithm that relies on HMM to take into account of the
correlations between aCGH markers (SNPs). We found
our HMMC algorithm to perform better than the NMF
clustering method, which is one of the most widely used
methods used for aCGH sample clustering.
Though HMM has been widely used in modelling cor-
related data, such as DNA copy number data, it is
widely known to be computationally very slow, espe-
cially for the analysis of high dimensional data such as
the aCGH data. In order to overcome this problem, we
have used various approaches to increase the computa-
tional efficiency and speed. First, in the clustering proce-
dure, we conduct a preliminary NMF clustering and the
resulting groups are used as the starting point for
HMMC.
Secondly, instead of performing exhausting search, we
only disturb the current optimal clustering with a few
random labelling. Thirdly, we implement the algorithm
in C++ that is much faster than R and MatLab. Further-
more, we have developed a parallel computing version
of the program, and it increases the speed by over 10-
f o l do u rs e r v e rc o m p u t e r .O u rt e s t i n go n7 9g l i o m a
samples showed that HMMC rapidly converges to its
optimal clustering and the computation time is linear to
the sample size.
Conclusions
In this manuscript we proposed a HMM-based cluster-
ing algorithm for identifying tumor subtypes using
aCGH DNA copy number data. This approach prop-
erly models the high spatial correlation between aCGH
markers. Clusters of tumor samples are modelled with
a mixture of HMM models where each HMM fits a
cluster of samples. We have developed a computation-
ally efficient and fast clustering algorithm that takes
only a computational time of O(n). We have shown
that this HMMC algorithm has less than half the error
rate of NMF clustering and it can locate the optimal
number of groups automatically while applying to
glioma aCGH data. The resulting clustering of glioma
samples has strong association with overall survival
time. This HMMC algorithm would potentially have
wide applications in tumor subtype identification,
genomic signature discovery, and diagnostic and prog-
nostic biomarker search. We will conduct future
research in extending HMM-based modelling to other
high dimensional biological data analysis, such as copy
number variation, gene set enrichment analysis, and
sequencing data analysis such as ChIP-seq data
processing.
Acknowledgements
Zhang’s research was supported in part by NIH grant 2P20RR016471-09,
North Dakota INBRE.
Author details
1Department of Pathology, School of Medicine and Health Sciences,
University of North Dakota, Grand Forks, ND 58201, USA.
2Exploratory
Statistics, Global Pharmaceutical Research & Development, Abbott
Laboratories, Abbott Park, IL 60064, USA.
3Department of Biochemistry and
Molecular Biology, School of Medicine and Health Sciences, University of
North Dakota, Grand Forks, ND 58201, USA.
4Department of Internal
Medicine, Rush University Medical Center, Chicago, IL 60612, USA.
Authors’ contributions
KZ conceived the study, developed the HMMC algorithm and implemented
it in R environment. YY wrote the C++ code for the methodology and
performed test for glioma data. VD and YD provided constructive
suggestions. KZ, VD, LX and DS wrote the manuscript with input from all
authors. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Published: 23 December 2011
References
1. Myrhoj T, Bisgaard ML, Bernstein I, Svendsen LB, Sondergaard JO, et al:
Hereditary non-polyposis colorectal cancer: clinical features and survival.
Results from the Danish HNPCC register. Scand J Gastroenterol 1997,
32:572-576.
2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al: Efficacy and
safety of trastuzumab as a single agent in first-line treatment of HER2-
overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
3. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, et al: Tamoxifen and
chemotherapy for lymph node-negative, estrogen receptor-positive
breast cancer. J Natl Cancer Inst 1997, 89:1673-1682.
4. Cleator SJ, Ahamed E, Coombes RC, Palmieri C: A 2009 update on the
treatment of patients with hormone receptor-positive breast cancer. Clin
Breast Cancer 2009, 9(Suppl 1):S6-S17.
5. Gazdar AF: Personalized medicine and inhibition of EGFR signaling in
lung cancer. N Engl J Med 2009, 361:1018-1020.
6. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al: Epidermal
Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in
Non-Small-Cell Lung Cancer. J Natl Cancer Inst 2005, 97:643-655.
7. Laurent-Puig P, Lievre A, Blons H: Mutations and response to epidermal
growth factor receptor inhibitors. Clin Cancer Res 2009, 15:1133-1139.
8. Harris M: Monoclonal antibodies as therapeutic agents for cancer. Lancet
Oncol 2004, 5:292-302.
9. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, et al: Epidermal Growth
Factor Receptor Gene Mutations and Increased Copy Numbers Predict
Gefitinib Sensitivity in Patients With Recurrent Non-Small-Cell Lung
Cancer. J Clin Oncol 2005, 23:6829-6837.
10. Tan DS, Reis-Filho JS: Comparative genomic hybridisation arrays: high-
throughput tools to determine targeted therapy in breast cancer.
Pathobiology 2008, 75:63-74.
11. Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, et al: Marked genomic
differences characterize primary and secondary glioblastoma subtypes
Zhang et al. BMC Genomics 2011, 12(Suppl 5):S10
http://www.biomedcentral.com/1471-2164/12/S5/S10
Page 8 of 9and identify two distinct molecular and clinical secondary glioblastoma
entities. Cancer Res 2006, 66:11502-11513.
12. Myllykangas S, Himberg J, Bohling T, Nagy B, Hollmen J, et al: DNA copy
number amplification profiling of human neoplasms. Oncogene 2006,
25:7324-7332.
13. Myllykangas S, Tikka J, Bohling T, Knuutila S, Hollmen J: Classification of
human cancers based on DNA copy number amplification modeling.
BMC Med Genomics 2008, 1:15.
14. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, et al: High-resolution
genomic profiles define distinct clinico-pathogenetic subgroups of
multiple myeloma patients. Cancer Cell 2006, 9:313-325.
15. Wang Y, Makedon F, Pearlman J: Tumor classification based on DNA copy
number aberrations determined using SNP arrays. Oncol Rep 2006,
15:1057-1059.
16. Lu X, Zhang K, Van Sant C, Coon J, Semizarov D: An algorithm for
classifying tumors based on genomic aberrations and selecting
representative tumor models. BMC Med Genomics 2010, 3:23.
17. Shah SP, Cheung KJ Jr, Johnson NA, Alain G, Gascoyne RD, et al: Model-
based clustering of array CGH data. Bioinformatics 2009, 25:i30-38.
18. Bengtsson H, Wirapati P, Speed TP: A single-array preprocessing method
for estimating full-resolution raw copy numbers from all Affymetrix
genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 2009,
25:2149-2156.
19. Olshen AB, Venkatraman ES, Lucito R, Wigler M: Circular binary
segmentation for the analysis of array-based DNA copy number data.
Biostatistics 2004, 5:557-572.
20. Breiman L: Random Forests. Machine Learning 2001, 45:5-32.
21. Hodgson G, Hager JH, Volik S, Hariono S, Wernick M, et al: Genome
scanning with array CGH delineates regional alterations in mouse islet
carcinomas. Nat Genet 2001, 29:459-464.
22. Chandra R: Parallel programming in OpenMP. San Francisco, CA: Morgan
Kaufmann Publishers; 2001:xvi:230.
23. (National Cancer Institute 2005) REMBRANDT home page. 2011 [http://
http//rembrandt.nci.nih.gov].
24. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, et al: Diffuse large B-cell
lymphoma outcome prediction by gene-expression profiling and
supervised machine learning. Nat Med 2002, 8:68-74.
25. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al: Molecular
classification of cancer: class discovery and class prediction by gene
expression monitoring. Science 1999, 286:531-537.
26. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al: Gene
expression profiling predicts clinical outcome of breast cancer. Nature
2002, 415:530-536.
27. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al: Distinct types of
diffuse large B-cell lymphoma identified by gene expression profiling.
Nature 2000, 403:503-511.
doi:10.1186/1471-2164-12-S5-S10
Cite this article as: Zhang et al.: A hidden Markov model-based
algorithm for identifying tumour subtype using array CGH data. BMC
Genomics 2011 12(Suppl 5):S10.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhang et al. BMC Genomics 2011, 12(Suppl 5):S10
http://www.biomedcentral.com/1471-2164/12/S5/S10
Page 9 of 9